TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28863021

Group type: EXPERIMENTAL
Intervention: 30° head rotation toward the ipsilateral side
Number of subjects: 41

Group type: COMPARATOR
Intervention: 30° head rotation toward the contralateral side
Number of subjects: 41

Group type: COMPARATOR
Intervention: Neutral head position
Number of subjects: 41

Group type: COMPARATOR
Intervention: Ipsilateral 30° head rotation
Number of subjects: 41
Study: 28863143

Group type: EXPERIMENTAL
Intervention: Direct spoligotyping on sputum
Number of subjects: 199

Group type: COMPARATOR
Intervention: Indirect spoligotyping on cultures
Number of subjects: 199

Group type: COMPARATOR
Intervention: Ancestral lineages (including M. africanum Lineages 5 and 6)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Lineage 5
Number of subjects: 199

Group type: COMPARATOR
Intervention: Lineage 4
Number of subjects: 199
Study: 28863774

Group type: EXPERIMENTAL
Intervention: Multifactorial fall prevention intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 28864403

Group type: EXPERIMENTAL
Intervention: TomoTherapy
Number of subjects: 166

Group type: COMPARATOR
Intervention: RapidArc
Number of subjects: 166
Study: 28864814

Group type: EXPERIMENTAL
Intervention: Rituximab 375 mg/m2 added to corticosteroids (CSs) and cyclosporine A (CsA) as first-line therapy for cGVHD.
Number of subjects: 24
Study: 28865109

Group type: EXPERIMENTAL
Intervention: Weight Loss Program (WL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moxonidine (M)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weight Loss Program (WL) + Moxonidine (WL + M)
Number of subjects: 0
Study: 28865448

Group type: EXPERIMENTAL
Intervention: LMA Supreme™
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Air-Q®
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Ambu® Aura-i™
Number of subjects: 240
Study: 28866036

Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffolds (BVS)
Number of subjects: 141
Study: 28866117

Group type: EXPERIMENTAL
Intervention: Mild absolute increase in SCr (0.25 to 0.50mg/dl)
Number of subjects: 3091

Group type: EXPERIMENTAL
Intervention: Mild relative increase in SCr (25% to 50%)
Number of subjects: 3091

Group type: EXPERIMENTAL
Intervention: Moderate increase in SCr (0.5 to 1.0mg/dl)
Number of subjects: 3091

Group type: EXPERIMENTAL
Intervention: Pre-existing renal dysfunction (eGFR<60ml/min)
Number of subjects: 3091

Group type: EXPERIMENTAL
Intervention: Large increase in SCr (>1.0mg/dl)
Number of subjects: 3091

Group type: EXPERIMENTAL
Intervention: Overall post-procedural increases in SCr (mild, moderate, large)
Number of subjects: 3091
Study: 28866290

Group type: EXPERIMENTAL
Intervention: PHiD-CV (2 doses for unprimed, 1 dose for primed)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (healthy age-matched children)
Number of subjects: 52
Study: 28866726

Group type: EXPERIMENTAL
Intervention: 6 week course of antibiotics
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 12 week course of antibiotics
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: WBC-SPECT/CT at 12 weeks
Number of subjects: 45
Study: 28866779

Group type: EXPERIMENTAL
Intervention: Live oral poliovirus vaccine (OPV)
Number of subjects: 315

Group type: COMPARATOR
Intervention: Inactivated poliovirus vaccine (IPV)
Number of subjects: 315
Study: 28867340

Group type: EXPERIMENTAL
Intervention: Higher-order contextual learning task
Number of subjects: 0
Study: 28867416

Group type: EXPERIMENTAL
Intervention: Emotion Regulation Skills (ERSQ) in MUS patients
Number of subjects: 458

Group type: COMPARATOR
Intervention: Emotion Regulation Skills (ERSQ) in MDD and MUS+MDD groups
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: Mediating effect of depression and anxiety in MUS groups
Number of subjects: 458
Study: 28867665

Group type: EXPERIMENTAL
Intervention: Oral baclofen (dosage not specified)
Number of subjects: 49
Study: 28868035

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 28869617

Group type: EXPERIMENTAL
Intervention: Yttrium-90 ibritumomab tiuxetan, dosage not specified, duration not specified
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 28869790

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MRI in HER2-positive patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MRI in tumours with Ki-67 ≥ 15%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MRI in tumours with Ki-67 < 15%
Number of subjects: 0
Study: 28869931

Group type: EXPERIMENTAL
Intervention: PXD-101 followed by Zevalin
Number of subjects: 5
Study: 28870219

Group type: EXPERIMENTAL
Intervention: Total screen viewing time (SVT) at age 2
Number of subjects: 910

Group type: EXPERIMENTAL
Intervention: Television viewing time at age 2
Number of subjects: 910

Group type: EXPERIMENTAL
Intervention: Hand-held device viewing time at age 2
Number of subjects: 910

Group type: EXPERIMENTAL
Intervention: Hand-held device SVT at age 3
Number of subjects: 910

Group type: EXPERIMENTAL
Intervention: Tracking of SVT from age 2 to 3
Number of subjects: 910

Group type: EXPERIMENTAL
Intervention: SVT by ethnicity at age 2
Number of subjects: 910

Group type: EXPERIMENTAL
Intervention: Predictors of longer SVT
Number of subjects: 910
Study: 28870232

Group type: EXPERIMENTAL
Intervention: SMARTgirl membership
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: High risk for ATS use disorder
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Overall HIV care
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: 12-month retention in care
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Viral suppression
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Reporting of STI symptoms
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Worse symptoms of psychological distress
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Greater numbers of sex partners
Number of subjects: 88
Study: 28870448

Group type: EXPERIMENTAL
Intervention: Nasal IL-25 protein level in NP tissues
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Nasal IL-25 protein level
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Nasal tissue IL-25
Number of subjects: 42
Study: 28870611

Group type: EXPERIMENTAL
Intervention: TargomiRs (miR-16-based mimic microRNA) administered via 20 min intravenous infusion either once or twice a week in a traditional 3+3 dose-escalation design in five dose cohorts.
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: TargomiRs
Number of subjects: 27
Study: 28870615

Group type: EXPERIMENTAL
Intervention: Luspatercept (0.75-1.75 mg/kg)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Luspatercept (0.125-0.5 mg/kg)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Luspatercept
Number of subjects: 58
Study: 28870716

Group type: EXPERIMENTAL
Intervention: MobiusHD device implanted unilaterally in the internal carotid artery
Number of subjects: 30
Study: 28870792

Group type: EXPERIMENTAL
Intervention: Bevacizumab with 11 Gy × 3 hypofractionated stereotactic reirradiation
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Bevacizumab with 10 Gy × 3 hypofractionated stereotactic reirradiation
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Bevacizumab with 9 Gy × 3 hypofractionated stereotactic reirradiation
Number of subjects: 15
Study: 28871029

Group type: EXPERIMENTAL
Intervention: Focus groups with service users
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Focus groups with clinicians
Number of subjects: 0
Study: 28871238

Group type: EXPERIMENTAL
Intervention: Educational intervention using the Traffic Light System (TLS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Educational intervention using the TLS
Number of subjects: 30
Study: 28871441

Group type: EXPERIMENTAL
Intervention: CytoSorb® adsorber applications (1 to 5 applications)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: CytoSorb® adsorber applications
Number of subjects: 198
Study: 28871961

Group type: EXPERIMENTAL
Intervention: CYD tetravalent dengue vaccine (CYD-TDV)
Number of subjects: 661

Group type: EXPERIMENTAL
Intervention: Vaccine strains
Number of subjects: 661
Study: 28872399

Group type: EXPERIMENTAL
Intervention: Participants living more than 3 miles from work
Number of subjects: 292

Group type: COMPARATOR
Intervention: Participants living within 3 miles of work
Number of subjects: 292

Group type: COMPARATOR
Intervention: Urban participants
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Nonurban participants
Number of subjects: 292
Study: 28872549

Group type: EXPERIMENTAL
Intervention: Zr-trastuzumab PET/CT
Number of subjects: 20
Study: 28873076

Group type: EXPERIMENTAL
Intervention: Propofol sedation using electroencephalogram monitoring during a constant level of sedation depth (D0 to D2) performed by trained nurses or physicians after a body-weight-adjusted loading dose.
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Propofol sedation
Number of subjects: 219
Study: 28873128

Group type: EXPERIMENTAL
Intervention: TDF/FTC (tenofovir disoproxil fumarate/emtricitabine) as PrEP for 48 weeks
Number of subjects: 78
Study: 28873162

Group type: EXPERIMENTAL
Intervention: Universal tumor-normal sequencing
Number of subjects: 1040
Study: 28874132

Group type: EXPERIMENTAL
Intervention: Bone turnover markers in patients on maintenance dialysis
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Bone turnover markers
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: PTH levels
Number of subjects: 157

Group type: COMPARATOR
Intervention: Fractured patients
Number of subjects: 157

Group type: COMPARATOR
Intervention: Fracture prevalence
Number of subjects: 157
Study: 28874164

Group type: EXPERIMENTAL
Intervention: CMR fluoroscopy guided right heart catheterization
Number of subjects: 39
Study: 28874545

Group type: EXPERIMENTAL
Intervention: Immune complexes composed of sialylated antihemagglutinin antibodies and seasonal inactivated flu vaccine (TIV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fc-modified, bispecific monoclonal antibody against conserved epitopes of the hemagglutinin combined with TIV
Number of subjects: 0
Study: 28874669

Group type: EXPERIMENTAL
Intervention: Patient-derived primary cultures (PDCs) for head and neck squamous cell carcinomas
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Comprehensive '-omics' interrogation of PDCs
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Treatment response in patient-derived models
Number of subjects: 2
Study: 28875153

Group type: EXPERIMENTAL
Intervention: Progressive high-load exercise (PHLE)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Low-load exercise (LLE)
Number of subjects: 100
Study: 28877563

Group type: EXPERIMENTAL
Intervention: IVT/EVT (n=22, IVT n=15, IVT+EVT n=3, EVT n=4)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: IVT
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: DNT
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Bleeding
Number of subjects: 114
Study: 28877664

Group type: EXPERIMENTAL
Intervention: BETACONNECT® autoinjector for IFN beta-1b
Number of subjects: 143
Study: 28877684

Group type: EXPERIMENTAL
Intervention: Smoking cessation intervention (not specified in detail, but includes nicotine replacement therapy or other cessation aids offered to 42% of smokers)
Number of subjects: 1083

Group type: COMPARATOR
Intervention: Unemployed or disability benefits
Number of subjects: 1083

Group type: COMPARATOR
Intervention: Low education
Number of subjects: 1083

Group type: COMPARATOR
Intervention: Longer smoking duration
Number of subjects: 1083

Group type: COMPARATOR
Intervention: Not having ST-elevation myocardial infarction (STEMI) as index event
Number of subjects: 1083

Group type: COMPARATOR
Intervention: Psychosocial factors at follow-up
Number of subjects: 1083

Group type: EXPERIMENTAL
Intervention: Motivation for cessation
Number of subjects: 1083

Group type: EXPERIMENTAL
Intervention: Risk perception of tobacco use
Number of subjects: 1083
Study: 28877686

Group type: EXPERIMENTAL
Intervention: ATRA combined with valproic acid and possibly low-toxicity conventional chemotherapy (low-dose cytarabine, hydroxyurea, 6-mercaptopurin)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: ATRA
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: ATRA and valproic acid
Number of subjects: 43
Study: 28877754

Group type: EXPERIMENTAL
Intervention: Mothers with Zika-like symptoms during pregnancy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-microcephalic babies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mothers classified as homemakers with past dengue infections
Number of subjects: 0
Study: 28877863

Group type: EXPERIMENTAL
Intervention: Topical 5% imiquimod cream, applied three times a week for 16 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Topical 5% imiquimod cream
Number of subjects: 20
Study: 28877894

Group type: EXPERIMENTAL
Intervention: Later circadian timing of food intake
Number of subjects: 0
Study: 28877944

Group type: EXPERIMENTAL
Intervention: External inspections of sepsis detection and treatment
Number of subjects: 24
Study: 28877948

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Guideline adherence for stable CAD patients
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Heart team evaluation
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Ischaemia testing
Number of subjects: 440
Study: 28878005

Group type: EXPERIMENTAL
Intervention: Citrate Anticoagulant
Number of subjects: 0
Study: 28878616

Group type: EXPERIMENTAL
Intervention: New electronic subretinal implant Alpha AMS
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 15
Study: 28878889

Group type: EXPERIMENTAL
Intervention: Goal-directed fluid volume optimization with hydroxyethyl starch and crystalloid fluid
Number of subjects: 97
Study: 28878932

Group type: EXPERIMENTAL
Intervention: Lifestyle program (the VEND-RISK Study)
Number of subjects: 332
Study: 28878934

Group type: EXPERIMENTAL
Intervention: Saxagliptin
Number of subjects: 110740
Study: 28879035

Group type: EXPERIMENTAL
Intervention: Educational programme with 2 days of lectures (group 1, 2, and 3) and bimonthly telephone calls
Number of subjects: 198
Study: 28879038

Group type: EXPERIMENTAL
Intervention: Functional and individualised neuromuscular exercise therapy (ET), 12 weeks, 3 sessions per week supervised by trained physical therapists.
Number of subjects: 60

Group type: COMPARATOR
Intervention: No attention control group (CG).
Number of subjects: 60
Study: 28879040

Group type: EXPERIMENTAL
Intervention: Combination of calcium channel blocker (CCB) with angiotensin receptor blocker (ARB)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Combination of thiazide diuretic with angiotensin receptor blocker (ARB)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Combination of calcium channel blocker (CCB) with ARB
Number of subjects: 119

Group type: COMPARATOR
Intervention: Combination of thiazide diuretic with ARB
Number of subjects: 119
Study: 28879043

Group type: EXPERIMENTAL
Intervention: Fully automated digital joint space width measurement
Number of subjects: 96

Group type: COMPARATOR
Intervention: Conventional radiographic scoring method (SHS)
Number of subjects: 96
Study: 28879052

Group type: EXPERIMENTAL
Intervention: Obese patients (BMI >30)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Non-obese patients (BMI <30)
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Current smoking
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: HAQ (per-unit increase)
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 260
Study: 28879248

Group type: EXPERIMENTAL
Intervention: Gingival crevicular fluid (GCF) levels of multiple cytokines and chemokines and RANKL:OPG ratio
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: IL-12p40, IL-6, IL-12p70, IL-2, and MIP-1α
Number of subjects: 58

Group type: COMPARATOR
Intervention: Plasma RANKL levels
Number of subjects: 58

Group type: COMPARATOR
Intervention: Plasma inflammatory profile including MIP-1α, IL-8, IL-10, and INF-γ
Number of subjects: 58
Study: 28879247

Group type: EXPERIMENTAL
Intervention: JP2 sequence
Number of subjects: 0

Group type: COMPARATOR
Intervention: non-JP2 sequence
Number of subjects: 0
Study: 28879519

Group type: EXPERIMENTAL
Intervention: Dabrafenib
Number of subjects: 0
Study: 28880374

Group type: EXPERIMENTAL
Intervention: Hydroxycarbamide (HC) treatment
Number of subjects: 21

Group type: COMPARATOR
Intervention: Untreated SCD patients
Number of subjects: 21
Study: 28880921

Group type: EXPERIMENTAL
Intervention: Urinary proteomic (UP) classifiers
Number of subjects: 352
Study: 28880943

Group type: EXPERIMENTAL
Intervention: Non-PV mediated AF
Number of subjects: 229

Group type: COMPARATOR
Intervention: PV-mediated AF
Number of subjects: 229
Study: 28881165

Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (PCV13)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 28881319

Group type: EXPERIMENTAL
Intervention: 25mg intravenous (IV) cocaine
Number of subjects: 8
Study: 28881389

Group type: EXPERIMENTAL
Intervention: Subcutaneous immunoglobulin (SCIg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous immunoglobulin (IVIg)
Number of subjects: 0
Study: 28881839

Group type: EXPERIMENTAL
Intervention: Decitabine (DAC) 20mg/m²
Number of subjects: 0
Study: 28881904

Group type: EXPERIMENTAL
Intervention: HPV positive status in Barrett's esophagus patients
Number of subjects: 180

Group type: COMPARATOR
Intervention: HPV positive status in control patients
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Association of HPV with Barrett's esophagus
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Factors associated with HPV
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Significance of HPV in the etiology of BE
Number of subjects: 180
Study: 28882117

Group type: EXPERIMENTAL
Intervention: Self-administered questionnaire regarding eye diseases awareness and practices
Number of subjects: 323
Study: 28882127

Group type: EXPERIMENTAL
Intervention: Frailty Index (FI) derived from Swiss RAI-HC
Number of subjects: 3714

Group type: EXPERIMENTAL
Intervention: Adverse health outcomes (falls, hospitalizations, mortality)
Number of subjects: 3714
Study: 28882141

Group type: EXPERIMENTAL
Intervention: 3-dimensional laparoscopy
Number of subjects: 400

Group type: COMPARATOR
Intervention: Conventional laparoscopy
Number of subjects: 400
Study: 28882349

Group type: EXPERIMENTAL
Intervention: Titanium clip-screw implant system
Number of subjects: 6
Study: 28882396

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 32
Study: 28882436

Group type: EXPERIMENTAL
Intervention: Rucaparib 600mg twice daily (BID)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Rucaparib 600mg BID
Number of subjects: 106
Study: 28882565

Group type: EXPERIMENTAL
Intervention: Oral calcium absorption study
Number of subjects: 20
Study: 28882811

Group type: EXPERIMENTAL
Intervention: Caffeine (coffee sachets with caffeine)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo (coffee sachets without caffeine)
Number of subjects: 66
Study: 28883080

Group type: EXPERIMENTAL
Intervention: Immunophenotypic expression profile
Number of subjects: 769
Study: 28883090

Group type: EXPERIMENTAL
Intervention: Incremental Shuttle Walk (ISW) before and after pulmonary rehabilitation (PR)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Incremental Shuttle Walk (ISW)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Minimum clinically important difference (MCID) estimates
Number of subjects: 122
Study: 28883894

Group type: EXPERIMENTAL
Intervention: LAP patients
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 20
Study: 28883928

Group type: EXPERIMENTAL
Intervention: Bubble continuous positive airway pressure (bCPAP)
Number of subjects: 900

Group type: COMPARATOR
Intervention: Low-flow oxygen (standard care)
Number of subjects: 900
Study: 28883932

Group type: EXPERIMENTAL
Intervention: 1000 international units per day of oral vitamin D
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28884264

Group type: EXPERIMENTAL
Intervention: CPC-CVHR algorithms applied to ECG data
Number of subjects: 47
Study: 28884487

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 10
Study: 28884840

Group type: EXPERIMENTAL
Intervention: Hydroxycarbamide (first dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydroxycarbamide (chronic therapy)
Number of subjects: 0
Study: 28885470

Group type: COMPARATOR
Intervention: Syndecan-1 concentrations within 10 hours of injury
Number of subjects: 17

Group type: COMPARATOR
Intervention: Thrombomodulin concentrations within 10 hours of injury
Number of subjects: 17
Study: 28885930

Group type: EXPERIMENTAL
Intervention: Therapeutic Lifestyle Changes (TLCs) including exercise, nutrition/diet, stress management and relaxation, time in nature, relationships, service to others, religious or spiritual involvement, and recreation.
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Therapeutic Lifestyle Changes (TLCs) through four classes and individual counseling over 9 weeks.
Number of subjects: 74
Study: 28886213

Group type: EXPERIMENTAL
Intervention: Obese group (BMI ≥30)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Normal weight group (BMI 18.5-29.9)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Underweight group (BMI <18.5)
Number of subjects: 600

Group type: COMPARATOR
Intervention: All groups compared
Number of subjects: 600
Study: 28886760

Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS) at 5 Hz, delivered in up to 40 daily sessions to the left dorsolateral prefrontal cortex
Number of subjects: 33
Study: 28887375

Group type: EXPERIMENTAL
Intervention: Intraventricular alteplase
Number of subjects: 464

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: CSF inflammatory measures
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Initial IVH volume exceeding 20 mL
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Culture-positive CSF bacterial infection
Number of subjects: 464